Prelude Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-121.83	-115.44	-111.69	-56.93	-27.57	Upgrade
Depreciation & Amortization	3.11	3.04	2.24	0.54	0.38	Upgrade
Share-Based Compensation	25.62	25.14	20.93	5.58	0.85	Upgrade
Other Operating Activities	-13.95	3.52	4.99	4.63	0.68	Upgrade
Operating Cash Flow	-107.06	-83.73	-83.53	-46.18	-25.67	Upgrade
Capital Expenditures	-3.51	-3.02	-2.32	-0.62	-0.78	Upgrade
Change in Investments	-31.13	84.71	-261.48	0	0	Upgrade
Investing Cash Flow	-34.65	81.69	-263.8	-0.62	-0.78	Upgrade
Share Issuance / Repurchase	136.41	0.82	165.2	166.73	0.01	Upgrade
Debt Issued / Paid	0	0	0	-0.26	-0.12	Upgrade
Other Financing Activities	-0.02	-	-0.3	79.76	29.85	Upgrade
Financing Cash Flow	136.4	0.82	164.9	246.23	29.73	Upgrade
Net Cash Flow	-5.31	-1.22	-182.44	199.43	3.28	Upgrade
Free Cash Flow	-110.58	-86.75	-85.85	-46.8	-26.45	Upgrade
Free Cash Flow Per Share	-1.83	-1.83	-1.86	-3.75	-15.85	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).